Open Orphan PLC (AIM:ORPH, FRA:CRO)'s (LON:ORPH) Cathal Friel talks to Proactive London about their year-on-year revenue growth and profitable first half following a 'year of turnaround and transition in 2020'.
As Friel explains, these results show a continued pattern of profitability from Q4 2020 to a firmly profitable position delivering a positive EBITDA profit of £2.1 million compared to an EBITDA loss of £4.1 million in H1 2020.
The company has also announced their subsidiary Hvivo has signed a £5.7 million contract with a specialist biotechnology company developing therapeutics for respiratory viral infections.